Current location - Trademark Inquiry Complete Network - Tian Tian Fund - What is Huatai Zijin trading hall for?
What is Huatai Zijin trading hall for?

This trading hall is for us to handle business. When handling some business, our users can choose business in this hall.

after the update, the lobby has been updated with some additional contents.

1. In terms of information, in addition to retaining the original content, the "favorite" column is set on the home page, including six sub-columns, such as analysis, live broadcast, special topics and famous artists. Customers can adjust the subscribed columns by themselves.

2. Service functions such as business handling, air financial planner and 95597 have been added.

3. A special column on Hong Kong stocks has been set up in the lobby to meet the requirements of business development.

4. The interface color has been greatly adjusted, which is more in line with the reading habits of PC-side customers.

5. Maintain interoperability with Fortune Connect and have their own characteristics to adapt to the different characteristics of mobile phones and PCs.

Huatai Zijin, established in 28, is a subsidiary of Huatai Securities, which specializes in equity investment. At present, the fund management scale of the company is nearly 5 billion yuan, and the medical and health field is one of the main tracks of concern. Chen Miao is mainly responsible for the project investment in medicine and diagnosis.

at present, Huatai Zijin has a layout in the three mainstream directions of medicine, medical devices and medical services. In terms of investment weight, the team invested the most in medicine, followed by medical devices and medical services, which was also positively related to the scale of the industry. "The diagnostic section is a field that Huatai is currently doing with more characteristics."

In terms of diagnostic projects, Huatai Zijin has listed Mindray Medical, Master Bio, Egg Bio and Pumen Technology, and Shihe Gene, Novozen, Xiansheng Diagnostics, Berger Medical and other companies are also actively preparing for the declaration, basically achieving full coverage of immune POCT, chemiluminescence, molecular diagnosis, NGS and other sub-industries.

Huatai Zijin also summed up some * * * criteria when selecting and judging projects. For example, the market size of the company's industry should be large enough, the management team should be excellent enough, and at the same time, the company itself has high technical barriers.